Moffitt researchers contribute to discovery of mechanism leading to drug resistance in prostate cancerJune 16th 2022
The Moffitt research team, in collaboration with scientists at Washington University in St. Louis, wanted to identify alternative resistance mechanisms to enzalutamide and abiraterone in prostate cancer patients.
FDA clears hyaluronic acid rectal spacer for use during prostate radiotherapyJune 15th 2022
Barrigel, which is made from Non-Animal Stabilized Hyaluronic Acid (NASHA), is used to separate and increase the distance between the anterior rectal wall and the prostate when the patient is receiving radiotherapy.
Dr. Armstrong on recent ARCHES data in metastatic hormone-sensitive prostate cancerJune 6th 2022
“We found in ARCHES that in the men who developed radiographic progression while on ADT-enzalutamide [Xtandi], two thirds of these patients, when they had radiographic progression, did not meet PSA progression criteria, and one third didn't have any rise at all in their PSA,” says Andrew J. Armstrong, MD, MSc.
Dr. Kibel discusses TRUS-guided and transperineal prostate biopsyJune 2nd 2022
"We're all very aware of the impact that prostate-specific antigen [PSA] has had on screening for prostate cancer. What's underappreciated is how the biopsy technique pivoted at about the same time," says Adam S. Kibel, MD.
At a glance: Single-port robot-assisted transvesical prostatectomiesJune 1st 2022
“Using the single-port robot with the transvesical approach allows us to go directly into the bladder, this means that we avoid the intraperitoneal cavity, which is not feasible with the multiport approach. This has led to less pain and postoperative ileus because the bowels stay intact,” says Jihad Kaouk, MD.
Urology Times 50 Innovations Series: Dr. Jennifer Linehan on HIFU for prostate cancerMay 25th 2022
"In trying to localize and focalize the treatment on just the lesion of prostate cancer, HIFU was incredibly powerful in the sense that it really allowed you to do that with great precision," said Jennifer Linehan, MD.
Sipuleucel-T: An innovative immunotherapy option for metastatic castration-resistant prostate cancerMay 19th 2022
In this installment of the Urology Times' 50th Anniversary Innovation Celebration, Kelvin A. Moses, MD, PhD, discusses the prostate cancer immunotherapy treatment sipuleucel-T (Provenge).
Patient Profile 6: Robotic Radical Prostatectomy for AdenocarcinomaMay 18th 2022
Dr Steven Finkelstein explains a clinical example of a 65-year-old patient with a history of robotic radical prostatectomy for Gleason 9 adenocarcinoma.